SHANGHAI, Dec 5 (Reuters) - China's Sichuan Kelun-Biotech Biopharmaceutical (6990.HK) said Thursday night it would license an ...

Pfizer’s VC arm has backed a $100 million series A raise for OTR Therapeutics, as the Chinese biotech tacks on preclinical ...

RA Capital Management’s Peter Kolchinsky says the companies that survived the industry’s 2021 rout are thriving—and looking ...

The companies Cogent Biosciences, Braveheart Bio, and AAVantgarde bagged the biggest biotech funding rounds overall in ...

Legend Biotech (LEGN) announced new long-term clinical and translational data for CARVYKTI from the CARTITUDE-1 and CARTITUDE-4 studies in ...

Laboratoires Théa has penned a deal potentially worth up to $280 million to get its hands on Iolyx Therapeutics’ phase ...

A Nobel laureate, he identified an enzyme that cuts DNA, laying the groundwork for milestones in scientific research and ...

Management has positioned bezuclastinib as a potential alternative to Blueprint Medicines' (BPMT) Ayvakit. This PDGFRα/c-KIT ...

The partnership will focus on Crescent’s PD-1/VEGF inhibitor CR-001 and Kelun-Biotech’s SKB105, both of which the companies ...

AI powers digital twins of cells/molecules, speeding early drug discovery and cutting trial-and-error work. Read more here.

Shares of Regeneron Pharmaceuticals (NASDAQ: REGN), a biotech giant, have been southbound over the past two years as the ...

Nanobiotix (NASDAQ: NBTX) is a French biotechnology stock, and one that has soared 660% in 2025 as of Nov. 18. That's enough ...